We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Convatec Group Plc | LSE:CTEC | London | Ordinary Share | GB00BD3VFW73 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-1.60 | -0.56% | 285.00 | 284.20 | 284.60 | 288.80 | 283.80 | 285.60 | 4,854,979 | 16:35:16 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Med, Dental, Hosp Eq-whsl | 2.14B | 130.3M | 0.0636 | 44.75 | 5.83B |
TIDMCTEC
RNS Number : 1281V
ConvaTec Group PLC
01 November 2017
ConvaTec Group Plc ("the Company") - Total Voting Rights
Reading, United Kingdom (1 November 2017)
The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. On 31 October 2017 the Company's issued capital with voting rights consists of 1,951,850,599 ordinary shares of 10p each. The Company does not hold any shares in Treasury at the date of this disclosure.
The above figure (1,951,850,599) can be used by shareholders as the denominator for the calculations by which to determine if they are required to notify their interest in, or a change to, their interest in the Company under the UK Financial Conduct Authority's Disclosure and Transparency Rules.
Enquiries
Media
Bobby Leach, VP Group Corporate Affairs, ConvaTec +44 (0)7770 842 226
Alastair Elwen, Finsbury +44 (0)207 251 3801
Analysts and Investors
John Crosse, VP Investor Relations, ConvaTec +44 (0)7500 141 435 Kirsty Law, Director Investor Relations, ConvaTec +44 (0)7470 909 582
investorrelations@convatec.com
ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92
About ConvaTec
ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. ConvaTec's products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com where a copy of this announcement can also be found.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVRZMMFGFMDGNZM
(END) Dow Jones Newswires
November 01, 2017 03:00 ET (07:00 GMT)
1 Year Convatec Chart |
1 Month Convatec Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions